INBRX-106 Adds a Randomized Response Signal in HNSCC

Evidence Source-gap catch-up · Published September 8, 2026 · Discovery September 8, 2026 · Importance 4/5 · Direction Positive Summary Inhibrx reported primary-endpoint results from the randomized Phase II portion of HexAgon in first-line, treatment-naive, PD-L1 CPS at least 20 metastatic or unresectable recurrent head…